Skip to main content
Year archive

Grand Pharmaceutical Group Limited — 2022 filings

All 49 regulatory filings released by Grand Pharmaceutical Group Limited (512) in 2022, sourced directly from the official regulator.

49 Filings
2022 Period
2022 filings (49)
Filing Released Lang
Terms of Reference of the Remuneration Committee
Remuneration Information
2022-12-29 English
VOLUNTARY ANNOUNCEMENT: THE CLINICAL TRIALS OF THE GROUPS INNOVATIVE ORAL SMALL MOLECULE 3CL PROTEASE INHIBITOR GS221 AGAINST COVID-19 ARE SUCCESSFULLY CONDUCTED
Regulatory Filings
2022-12-28 English
CONNECTED TRANSACTION : SUBSCRIPTION FOR NEW SHARES IN GRAND PHARMA SPHERE PTE LTD.
Capital/Financing Update
2022-12-15 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 NOVEMBER 2022
Regulatory Filings
2022-12-02 English
VOLUNTARY ANNOUNCEMENT: THE GLOBAL INNOVATIVE RADIONUCLIDE-DRUG CONJUGATE TLX250-CDX OVERSEAS PHASE III CLINICAL TRIAL HAS MET CLINICAL ENDPOINTS
Regulatory Filings
2022-11-10 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 OCTOBER 2022
Regulatory Filings
2022-11-01 English
VOLUNTARY ANNOUNCEMENT: THE GROUP'S GLOBAL INNOVATIVE PRODUCT STC3141 ACHIEVED THE CLINICAL ENDPOINT OF THE PHASE Ib CLINICAL TRIAL FOR THE TREATMENT OF ARDS IN CHINA
Regulatory Filings
2022-10-31 English
VOLUNTARY ANNOUNCEMENT: THE CLINICAL TRIAL APPLICATION IN CHINA FOR GLOBAL INNOVATIVE RADIONUCLIDE-DRUG CONJUGATE TLX591-CDx WAS APPROVED BY NMPA
Regulatory Filings
2022-10-17 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 SEPTEMBER 2022
Regulatory Filings
2022-10-06 English
THE CLINICAL TRIAL APPLICATION IN CHINA FOR GLOBAL INNOVATIVE RADIONUCLIDE-DRUG CONJUGATE TLX250-CDX WAS APPROVED BY NMPA
Regulatory Filings
2022-09-28 English
INTERIM REPORT 2022
Regulatory Filings
2022-09-27 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 AUGUST 2022
Regulatory Filings
2022-09-05 English
VOLUNTARY ANNOUNCEMENT: UPDATE ON STRATEGIC INVESTMENT IN TELIX
Capital/Financing Update
2022-08-12 English
2022 INTERIM RESULTS ANNOUNCEMENT
Interim / Quarterly Report
2022-08-10 English
PROFIT ALERT
Regulatory Filings
2022-08-08 English
VOLUNTARY ANNOUNCEMENT: THE GROUP ACQUIRED 100% EQUITY OF AN AMINO ACID MANUFACTURING COMPANY
Capital/Financing Update
2022-08-07 English
PROFIT ALERT
Regulatory Filings
2022-08-05 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JULY 2022
Regulatory Filings
2022-08-01 English
VOLUNTARY ANNOUNCEMENT: THE CLINICAL TRIAL APPLICATIONS IN CHINA FOR GLOBAL INNOVATIVE RADIONUCLIDE-DRUG CONJUGATES TLX591-CDX AND TLX250-CDX WERE ACCEPTED BY NMPA
Regulatory Filings
2022-08-01 English
DATE OF BOARD MEETING
Regulatory Filings
2022-07-29 English
VOLUNTARY ANNOUNCEMENT: THE GROUP'S GLOBAL INNOVATIVE PRODUCT STC3141 COMPLETED THE ENROLLMENT AND DOSING OF ALL PATIENTS IN THE PHASE Ib CLINICAL TRIAL FOR THE TREATMENT OF ARDS IN CHINA & A
Regulatory Filings
2022-07-27 English
VOLUNTARY ANNOUNCEMENT: THE GROUP INTRODUCED A GLOBAL INNOVATIVE ENDOGENOUS TISSUE REPAIR PRODUCT
Capital/Financing Update
2022-07-18 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 JUNE 2022
Regulatory Filings
2022-07-04 English
SUPPLEMENTAL ANNOUNCEMENT: CONTINUING CONNECTED TRANSACTION DISTRIBUTION AGREEMENT WITH SIRTEX MEDICAL
Regulatory Filings
2022-06-24 English
CONTINUING CONNECTED TRANSACTION: DISTRIBUTION AGREEMENT WITH SIRTEX MEDICAL
Regulatory Filings
2022-06-02 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MAY 2022
Share Issue/Capital Change
2022-06-02 English
SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 27 MAY 2022
Declaration of Voting Results & Voting Rights Announcements
2022-05-27 English
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 27 MAY 2022
Declaration of Voting Results & Voting Rights Announcements
2022-05-27 English
VOLUNTARY ANNOUNCEMENT: THE GROUP HAS REACHED A STRATEGIC COOPERATION AND SIGNED A TECHNOLOGY AND INTELLECTUAL PROPERTY PRODUCT TRANSFER AGREEMENT WITH THE EYE HOSPITAL OF WENZHOU MEDICAL UNIVERSITY
Capital/Financing Update
2022-05-25 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 APRIL 2022
Regulatory Filings
2022-05-05 English
CONNECTED TRANSACTION: CAPITAL INJECTION INTO A JOINT VENTURE COMPANY
Capital/Financing Update
2022-04-27 English
VOLUNTARY ANNOUNCEMENT: THE GLOBAL INNOVATIVE PRODUCT STC3141 OF THE GROUP IS APPROVED FOR PHASE Ib CLINICAL STUDY FOR TREATMENT OF SEPSIS IN BELGIUM
Regulatory Filings
2022-04-26 English
Final dividend for the year ended 31 December 2021 (Update)
Notice of Dividend Amount
2022-04-25 English
Proxy form for the annual general meeting to be held on 27 May 2022 or any adjournment thereof
Proxy Solicitation & Information Statement
2022-04-25 English
Notice of Annual General Meeting
AGM Information
2022-04-25 English
(1) GENERAL MANDATE TO REPURCHASE SHARES AND ISSUE NEW SHARES&#x3b; (2) RE-ELECTION OF RETIRING DIRECTORS&#x3b; AND (3) NOTICE OF ANNUAL GENERAL MEETING
AGM Information
2022-04-25 English
Annual Report 2021
Regulatory Filings
2022-04-25 English
VOLUNTARY ANNOUNCEMENT: PHASE III CLINICAL TRIAL OF GLOBAL INNOVATIVE DRUG RYALTRIS COMPOUND NASAL SPRAY SUCCESSFULLY COMPLETED THE FIRST PATIENT ENROLLMENT IN CHINA
Regulatory Filings
2022-04-07 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MARCH 2022
Regulatory Filings
2022-04-04 English
VOLUNTARY ANNOUNCEMENT: SHARE PURCHASE PURSUANT TO SHARE AWARD SCHEME
Transaction in Own Shares
2022-03-21 English
Final dividend for the year ended 31 December 2021
Notice of Dividend Amount
2022-03-18 English
ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2021
Annual Report
2022-03-17 English
DATE OF BOARD MEETING
Regulatory Filings
2022-03-07 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 28 FEBRUARY 2022
Regulatory Filings
2022-03-02 English
VOLUNTARY ANNOUNCEMENT: THE GROUP ENTERED AN EQUITY INVESTMENT AGREEMENT WITH ITM ISOTOPE TECHNOLOGIES MUNICH SE IN GERMANY
Capital/Financing Update
2022-02-16 English
VOLUNTARY ANNOUNCEMENT: THE GLOBAL INNOVATIVE RADIOPHARMACEUTICAL OF THE GROUP SIR-SPHERES Y-90 MICROSPHERE INJECTION WERE APPROVED FOR COMMERCIALIZATION IN CHINA BY THE NATIONAL MEDICAL PRODUCT ADMIN
Regulatory Filings
2022-02-09 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JANUARY 2022
Regulatory Filings
2022-02-07 English
SUPPLEMENTAL ANNOUNCEMENT: CONNECTED TRANSACTIONS IN RESPECT OF THE CONSULTANCY AGREEMENTS
Regulatory Filings
2022-01-11 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 DECEMBER 2021
Regulatory Filings
2022-01-04 English